孟鲁司特联合雾化吸入氨溴索治疗慢性阻塞性肺疾病的临床研究

目的:探讨孟鲁司特片联合雾化吸入氨溴索治疗慢性阻塞性肺疾病的疗效。方法:选择慢性阻塞性肺疾病患者120例,随机分为治疗组和对照组,每组各60例。对照组:予抗感染等常规治疗。治疗组:予常规治疗同时加用口服孟鲁司特片10 mg,1次/晚;氨溴索注射液30 mg雾化吸入,2次/d,疗程2周。观察患者咳嗽、咯痰、喘息等主要临床症状明显缓解所需要时间及住院时间,并随访6个月观察复发情况。结果:治疗组患者咳嗽、咯痰、喘息等主要临床症状明显缓解所需要时间明显少于对照组,差异有统计学意义(P<0.01);治疗组住院时间少于对照组,并可减少复发次数,差异有统计学意义(P<0.05)。结论:孟鲁司特片联合雾化吸入氨溴索可以更有效地治疗和控制慢性阻塞性肺疾病,值得临床进一步推广。

The clinical research on montelukast joint atomization inhalation of ambroxol in the treatment of chronic obstructive pulmonary disease

Objective To explore the curative effect that montelukast joint atomization inhalation of ambroxol in the treatment of chronic obstructive pulmonary disease.Methods 120 patients were randomly divided into treatment group and control group,which have been diagnosed as chronic obstructive pulmonary disease in the respiratory medicine.Each group contained 60 patients.The method of treatment in control group was routine treatment.Excepting the routine treatment,treatment group also added that,oral montelukast piece(10 mg,qn),and atomization inhalation of ambroxol(30 mg,bid).The treatment course was 2 weeks.To observe days abou major clinical symptoms,such as cough,cough up phlegm,wheeze,which were obviously remitted.We also observed the hospital days of patients,and followed up patients for six months in order to observe the recurrence rate of COPD.Results The days abou major clinical symptoms which were obviously remitted in treatment group were less than control group(P<0.01).In the meantime,the hospital days and the recurrence rate of COPD were less than control group(P<0.05).Conclusion Montelukast joint atomization inhalation of ambroxol in the treatment of chronic obstructive pulmonary disease have an obvious positive effect.